金陵药业
(000919)
| 流通市值：38.31亿 | | | 总市值：40.48亿 |
| 流通股本：5.90亿 | | | 总股本：6.24亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,220,261,162.73 | 1,510,974,167.63 | 746,529,645.21 | 2,785,738,409.8 |
| 营业收入 | 2,220,261,162.73 | 1,510,974,167.63 | 746,529,645.21 | 2,785,738,409.8 |
| 二、营业总成本 | 2,142,170,897.07 | 1,429,289,464.88 | 686,037,920.77 | 2,696,710,376.6 |
| 营业成本 | 1,770,400,774.84 | 1,194,119,580.36 | 576,634,343 | 2,199,625,120.9 |
| 税金及附加 | 14,856,726.04 | 10,006,341.15 | 4,298,067.62 | 18,620,537.86 |
| 销售费用 | 67,467,572.06 | 35,535,253.14 | 6,808,746.96 | 86,166,082.15 |
| 管理费用 | 239,296,887.95 | 161,034,906.83 | 80,910,187.96 | 335,704,508.6 |
| 研发费用 | 64,403,035.8 | 37,625,764.23 | 20,776,182.16 | 79,143,338.26 |
| 财务费用 | -14,254,099.62 | -9,032,380.83 | -3,389,606.93 | -22,549,211.17 |
| 其中:利息费用 | 59,542.81 | 45,411.31 | 21,929.06 | 230,957.01 |
| 其中:利息收入 | 14,730,509.21 | 9,338,732.93 | 3,546,605.06 | 23,897,015.59 |
| 加:公允价值变动收益 | 17,868,995.47 | 912,611.67 | 1,520,240.3 | -2,252,785.8 |
| 加:投资收益 | -6,751,210.62 | -12,794,085.24 | 1,141,434.47 | 18,895,622.55 |
| 资产处置收益 | 124,411.49 | -26,206.7 | -42,821.51 | -97,454.75 |
| 资产减值损失(新) | 19,683.1 | - | - | -337,473.35 |
| 信用减值损失(新) | -5,389,403.11 | -2,033,338.41 | -3,970,839.9 | -1,608,669.45 |
| 其他收益 | 7,439,936.25 | 4,106,355.16 | 1,801,446.7 | 13,370,532.34 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 91,402,678.24 | 71,850,039.23 | 60,941,184.5 | 116,997,804.74 |
| 加:营业外收入 | 1,608,332.2 | 637,629.84 | 214,950.01 | 2,832,578.64 |
| 减:营业外支出 | 626,351.31 | 352,223.24 | 637.72 | 1,409,289.67 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 92,384,659.13 | 72,135,445.83 | 61,155,496.79 | 118,421,093.71 |
| 减:所得税费用 | 20,230,217.89 | 15,867,195.22 | 13,988,183.78 | 11,233,940.71 |
| 六、净利润 | 72,154,441.24 | 56,268,250.61 | 47,167,313.01 | 107,187,153 |
| 持续经营净利润 | 72,154,441.24 | 56,268,250.61 | 47,167,313.01 | 107,187,153 |
| 归属于母公司股东的净利润 | 71,368,654.3 | 51,818,796.27 | 43,544,728.75 | 99,652,601.77 |
| 少数股东损益 | 785,786.94 | 4,449,454.34 | 3,622,584.26 | 7,534,551.23 |
| (一)基本每股收益 | 0.12 | 0.09 | 0.08 | 0.2 |
| (二)稀释每股收益 | 0.12 | 0.09 | 0.08 | 0.2 |
| 八、其他综合收益 | 39,230.41 | - | - | - |
| 归属于母公司股东的其他综合收益 | 39,230.41 | - | - | - |
| 九、综合收益总额 | 72,193,671.65 | 56,268,250.61 | 47,167,313.01 | 107,187,153 |
| 归属于母公司股东的综合收益总额 | 71,407,884.71 | 51,818,796.27 | 43,544,728.75 | 99,652,601.77 |
| 归属于少数股东的综合收益总额 | 785,786.94 | 4,449,454.34 | 3,622,584.26 | 7,534,551.23 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |